Literature DB >> 30755733

Base excision repair regulates PD-L1 expression in cancer cells.

Tiara Bunga Mayang Permata1,2, Yoshihiko Hagiwara1, Hiro Sato1, Takaaki Yasuhara3, Takahiro Oike1, Soehartati Gondhowiardjo2, Kathryn D Held4,5, Takashi Nakano1, Atsushi Shibata6.   

Abstract

Programmed death-ligand 1 (PD-L1) is a key factor influencing cancer immunotherapy; however, the regulation of PD-L1 expression in cancer cells remains unclear, particularly regarding DNA damage, repair and its signalling. Herein, we demonstrate that oxidative DNA damage induced by exogenously applied hydrogen peroxide (H2O2) upregulates PD-L1 expression in cancer cells. Further, depletion of the base excision repair (BER) enzyme DNA glycosylase augments PD-L1 upregulation in response to H2O2. PD-L1 upregulation in BER-depleted cells requires ATR/Chk1 kinase activities, demonstrating that PD-L1 upregulation is mediated by DNA damage signalling. Further analysis of The Cancer Genome Atlas revealed that the expression of PD-L1 is negatively correlated with that of the BER/single-strand break repair (SSBR) and tumours with low BER/SSBR gene expression show high microsatellite instability and neoantigen production. Hence, these results suggest that PD-L1 expression is regulated in cancer cells via the DNA damage signalling and neoantigen-interferon-γ pathway under oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30755733     DOI: 10.1038/s41388-019-0733-6

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

Review 1.  The relative biological effectiveness of proton irradiation in dependence of DNA damage repair.

Authors:  Simon Deycmar; Erica Faccin; Tamara Kazimova; Philip A Knobel; Irma Telarovic; Fabienne Tschanz; Verena Waller; Rona Winkler; Carmen Yong; Dario Zingariello; Martin Pruschy
Journal:  Br J Radiol       Date:  2019-11-11       Impact factor: 3.039

Review 2.  Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors:  Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal:  Nat Rev Cancer       Date:  2021-08-10       Impact factor: 60.716

3.  Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.

Authors:  Yihe Yan; Leting Zheng; Qiang Du; Bing Yan; David A Geller
Journal:  Cancer Immunol Immunother       Date:  2020-05-06       Impact factor: 6.968

Review 4.  Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.

Authors:  Reham Ajina; David J Zahavi; Yong-Wei Zhang; Louis M Weiner
Journal:  Semin Cancer Biol       Date:  2019-12-19       Impact factor: 15.707

Review 5.  Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.

Authors:  Chen Chen; Yanlong Liu; Binbin Cui
Journal:  Hum Vaccin Immunother       Date:  2021-01-11       Impact factor: 3.452

Review 6.  Role of DNA repair defects in predicting immunotherapy response.

Authors:  Jing Zhang; David J H Shih; Shiaw-Yih Lin
Journal:  Biomark Res       Date:  2020-06-29

7.  CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas.

Authors:  Bangbao Tao; Juanhong Shi; Shuai Shuai; Haiyan Zhou; Hongxia Zhang; Bin Li; Xiaoqiang Wang; Guohui Li; Hua He; Jun Zhong
Journal:  J Transl Med       Date:  2021-08-09       Impact factor: 5.531

8.  Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.

Authors:  Kailiang Zhao; Qiang Zhang; Sheryl A Flanagan; Xueting Lang; Long Jiang; Leslie A Parsels; Joshua D Parsels; Weiping Zou; Theodore S Lawrence; Rémi Buisson; Michael D Green; Meredith A Morgan
Journal:  Mol Cancer Res       Date:  2021-05-27       Impact factor: 5.852

Review 9.  NF-κB and Its Role in Checkpoint Control.

Authors:  Annika C Betzler; Marie-Nicole Theodoraki; Patrick J Schuler; Johannes Döscher; Simon Laban; Thomas K Hoffmann; Cornelia Brunner
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

Review 10.  Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.

Authors:  Hiro Sato; Noriyuki Okonogi; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2020-04-03       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.